Mode
Text Size
Log in / Sign up
N/A N=30 Randomized Double-blind Treatment

Cognitive Training in Parkinson's Disease

Parkinson Disease

Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Change in Quality of Life in Neurological Disorders Cognitive Function Version 2 (Neuro-QoL CF v2) T-scores at 6 Weeks — 49.9; 49.1; 50; 45.9 T-score — p=0.015

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Mental Imagery Training (Behavioral); Psychoeducation (Behavioral)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
Yale University
Primary completion
Sep 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Quality of Life in Neurological Disorders Cognitive Function Version 2 (Neuro-QoL CF v2) T-scores at 6 Weeks
49.9; 49.1; 50; 45.9 0.015 sig
PRIMARY
Change in Neuro-QoL CF v2 T-scores at 18 Weeks
49.9; 49.1; 49.4; 46.9 0.993
SECONDARY
Change in Composite Executive Function T-scores at 6 Weeks
53.1; 48.7; 54.7; 51 0.517
SECONDARY
Change in Composite Executive Function T-scores at 18 Weeks
53.1; 48.7; 55.1; 49.5 0.817

Summary

The purpose of this research study is to determine whether cognitive training will improve cognitive and brain functions in people with Parkinson's Disease (PD) during activities of daily living using cognitive evaluations and magnetic resonance imaging (MRI).

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of idiopathic PD
  • Age ≥ 40 years
  • Expected to be on a stable dopaminergic medication regimen throughout the study period

Exclusion Criteria

  • Non-English speaking
  • Pregnancy
  • Breastfeeding
  • Excessive alcohol consumption (> 7 drinks per week for women, > 14 drinks per week for men) or illicit substance use
  • History of a neurological disorder such as a brain tumor, stroke, central nervous system infection, multiple sclerosis, movement disorder (other than PD), or seizures
  • History of schizophrenia, bipolar disorder, attention deficit disorder, or obsessive-compulsive disorder
  • History of head injury with loss of consciousness longer than a few minutes
  • Metallic surgical implants or traumatically implanted metallic foreign bodies
  • Inability to lie flat for about an hour in the MRI scanner
  • Discomfort being in small, enclosed spaces
  • Dementia at screening (Montreal Cognitive Assessment score 4)
  • Mild cognitive impairment according to the Movement Disorders Society (MDS) Level II comprehensive assessment criteria (> 1.5 standard deviations below the norm in two tests in a single cognitive domain or in one test in two separate cognitive domains, with the exception that the executive domain scores can be up to 2 standard deviations below the norm)
  • Hoehn & Yahr stage > 3 (i.e., able to stand and walk, but not fully independent)
  • Focal neurological findings on exam that suggest cerebral pathology other than that associated with parkinsonism
  • Motor symptoms that could potentially introduce too much motion artifact in the imaging data (e.g., MDS-Unified PD Rating Scale resting tremor score > 2 in limbs, head/chin tremor, or more than mild dyskinesia by history or exam)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05495997). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search